SB 819 redirects $4,906,630 from an unappropriated surplus balance in West Virginia's General Revenue Fund to William R. Sharpe Jr. Hospital (fund 0413) for fiscal year 2026. The bill supplements the hospital's existing appropriation by adding a new line item for "Current Expenses - Surplus" to cover operational costs. This procedural budget adjustment directly affects the hospital's funding for the 2026 fiscal year without changing health care policies or creating new obligations. The funds were identified in the Governor's Executive Budget Document as available surplus.
SB 828 is a procedural bill that allocates unspent funds from the Department of Human Services' Medicaid State Share Fund (Fund 5090) for fiscal year 2026. It directs $174,483,090 already designated for "Medical Services" to cover ongoing Medicaid provider payments, using money remaining unappropriated after the fiscal year began. This bill does not create new policy or change eligibility - it simply ensures existing unspent Medicaid funds are used for medical services as intended. It directly affects Medicaid providers in West Virginia by securing payment for covered services.
SB 897 establishes licensing and certification requirements for alcohol and drug counselors in West Virginia. It defines key terms like "substance use disorder" and "practice of alcohol and drug counseling," which includes evaluating addiction issues, developing treatment plans, and providing trauma-informed care. The bill sets eligibility criteria, application fees, renewal fees, and grandfathering provisions for existing counselors based on education or experience. It also creates disciplinary actions for violations and specifies exceptions for healthcare providers, state employees, and self-help groups. This bill directly affects counselors seeking to provide substance use disorder treatment services in the state.
SB 741 expands the pilot program for involuntary commitment processes to include additional counties: Cabell, Berkeley, Hampshire, Morgan, Ohio, and Wood. The bill requires mental health centers in these counties to provide timely evaluations (in-person or via video) for potential commitment and explain the process to affected individuals. It also mandates quarterly audits of commitment applications to ensure clinical justification, with findings kept confidential. This bill directly affects mental health centers, courts, law enforcement, and individuals subject to involuntary commitment in the expanded counties.
This bill allows doctors in West Virginia to legally prescribe, distribute, and market specific forms of psilocybin once the FDA approves it and the DEA reschedules it. It amends state pharmacy laws to remove barriers for FDA-approved crystalline polymorph psilocybin products, aligning state regulations with federal decisions. The law applies only to pharmaceutical compositions of psilocybin that meet federal approval standards, not to raw or unapproved forms of the substance. Healthcare providers and pharmacies would be able to handle these medications under existing prescription drug frameworks once federal requirements are met.
This bill establishes a value-based payment system for West Virginia's Medicaid addiction care services, shifting from fee-for-service to rewarding providers based on patient recovery outcomes. It directly affects Medicaid providers treating substance use disorders by requiring them to use standardized billing codes starting in 2027 and report on five specific outcome metrics: housing stability, sobriety, avoidance of criminal justice involvement, self-sufficiency (employment/education), and provider transition plans. The bill mandates data collection and analysis by the Bureau for Medical Services to develop these metrics, with value-based payments requiring implementation by 2028. The goal is to create a coordinated care system focused on long-term recovery success rather than fragmented service volume.
SB 650 amends West Virginia law to define a psychiatric hospital treating exclusively civil and forensic patients (with over 95% of its inpatient census being court-ordered forensic or civil involuntary commitments from state custody) as a "state-designated facility" for tax purposes. This change excludes such hospitals from the category of "eligible acute care hospitals" subject to a 0.75% tax on gross receipts, exempting them from this tax. The bill directly affects psychiatric hospitals in West Virginia meeting this specific patient mix requirement by altering their tax classification under the Medicaid funding structure.
This bill (SB 570) allocates $199,476,099 in unspent federal funds to the West Virginia Department of Health's "Rural Health Transformation Program" for fiscal year 2026. It adds a new funding line (Fund 8802, Org 0506) under the Department's Central Office to support this specific program. The funds are designated for rural health initiatives and directly affect the Department of Health's ability to implement these programs. This is a procedural funding measure, not a policy change, using existing federal funds without new tax implications.
HB 4626 establishes a West Virginia grant program to fund U.S. Food and Drug Administration (FDA) drug development trials using ibogaine, a substance being studied for treating opioid use disorder and other neurological/mental health conditions. The program requires applicants (e.g., pharmaceutical companies or research organizations) to demonstrate capacity to conduct FDA trials, secure approval for ibogaine as a medication, and commit to establishing a state presence, securing insurance coverage, and ensuring treatment access for uninsured patients. Applicants must submit detailed trial designs, safety protocols, and plans for intellectual property rights and post-approval implementation, with grants administered through a state selection committee. The bill does not approve ibogaine but aims to accelerate its development pathway through state-funded trials.
SB 805 adds "abortion pill reversal" to West Virginia's Mothers and Babies Pregnancy Support Program, allowing funding for this service through eligible pregnancy help organizations. The bill defines "abortion pill reversal" as using progesterone to counteract the abortion pill (mifepristone) and specifies that only organizations that do not support or perform abortions can receive program funds for this purpose. Abortion industry organizations are explicitly excluded from receiving these funds. This is a procedural change to the existing program's funding eligibility, not a new law restricting abortion access.
